Caregen (CEO Yongji Jeong), a biopharmaceutical company specializing in peptides, announced on the 12th that it has signed a supply contract for three health functional foods with Canadian wellness brand VANA Health. Under this contract, Caregen has tentatively agreed to supply a total of $158 million (approximately KRW 210 billion) worth of products, including three of its core functional peptides: Korglutide (USD 54 million), MyoKi (USD 54 million), and ProGsterol (USD 50 million), over the next three years.
VANA Health, based in London and Vancouver, operates the premium liquid supplement brand "VANA AM·PM." Its product promotion and distribution experience stems from elite sports networks, including the Canadian national snowboarding team. This agreement will see Caregen's high-performance ingredients incorporated into VANA Health's product lineup, providing customized health solutions to North American consumers.
Notably, this supply agreement goes beyond general product supply. Key to this agreement is its integration with VANA Health's real-time health monitoring and personalized recommendation platform, operated by its affiliates eSensorem and Monarch Longevity. eSensorem is a startup developing non-invasive patch-type biosensors that measure various metabolic indicators, including blood sugar, lactate, pH, moisture, and electrolytes, in real time.
eSensorem's core research team is led by Chief Scientist Dr. Yangzhi Zhu, along with global talent including CTO Gregor Berkowitz, who has global experience in AI, healthcare, and consumer products, and Tom Gilley, a former R&D manager at Apple's Advanced Technology Group (ATG). Dr. Zhu's technological innovation and research achievements were recognized by the international academic community, winning the 2024 Biosensors Young Investigator Award.
Monarch Longevity is an AI-powered longevity and wellness platform that analyzes data collected through eSensorem sensors to suggest personalized diet, exercise, and supplement plans. Caregen's products are recommended and consumed based on individual biometric data, with immediate monitoring of efficacy. This allows Caregen to differentiate itself as a "peptide health functional food with proven immediate effects," while VANA Health strengthens its science-based wellness brand image in the North American market.
Caregen CEO Yong-ji Jeong said, “This Canadian supply contract is an innovative collaboration model that provides customized health solutions that consumers can feel by linking Caregen’s functional peptides with VANA Health’s AI and biosensor-based platform.” He added, “As Caregen’s high-functionality products, such as Korglutide, Myoki, and ProGsterol, will demonstrate optimized effects through real-time data analysis by eSensorem and Monarch Longevity, we expect to kill two birds with one stone: proving product efficacy and enhancing brand reliability in the North American market.”
“Caregen’s ProGsterol, Myoki, and Korglutide each have functions that are directly linked to eSensorem’s real-time measurement indicators, such as blood sugar stabilization, muscle recovery, and weight control,” said Sak Narwal, CEO of VANA Health. “Through this collaboration, consumers will be able to select and consume the most suitable health functional food based on their health data and see immediate effects.”
- See more related articles
You must be logged in to post a comment.